These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 37861033)

  • 1. VEGF165b Mutant Promotes the Apoptosis of Murine Breast Cancer Cells Induced by Paclitaxel by Inducing Tumor Vessel Maturation.
    Liang C; Li Y; Guo E; Bai S; Wang Y; Zhang H
    Protein Pept Lett; 2023; 30(11):951-958. PubMed ID: 37861033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of paclitaxel and nab-paclitaxel in combination with anti-angiogenic therapy in breast cancer cell lines.
    Tonissi F; Lattanzio L; Merlano MC; Infante L; Lo Nigro C; Garrone O
    Invest New Drugs; 2015 Aug; 33(4):801-9. PubMed ID: 25947567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined anti-angiogenic therapy against VEGF and integrin alphaVbeta3 in an orthotopic model of ovarian cancer.
    Kim TJ; Landen CN; Lin YG; Mangala LS; Lu C; Nick AM; Stone RL; Merritt WM; Armaiz-Pena G; Jennings NB; Coleman RL; Tice DA; Sood AK
    Cancer Biol Ther; 2009 Dec; 8(23):2263-72. PubMed ID: 19829059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. VEGF165b and its mutant demonstrate immunomodulatory, not merely anti-angiogenic functions, in tumor-bearing mice.
    Zhang H; Xia W; Liang C; Wang X; Zhi L; Guo C; Niu Z; Zhu W
    Mol Immunol; 2020 Apr; 122():132-140. PubMed ID: 32353584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the insulin growth factor and the vascular endothelial growth factor pathways in ovarian cancer.
    Shao M; Hollar S; Chambliss D; Schmitt J; Emerson R; Chelladurai B; Perkins S; Ivan M; Matei D
    Mol Cancer Ther; 2012 Jul; 11(7):1576-86. PubMed ID: 22700681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. VEGF165b mutant with a prolonged half-life and enhanced anti-tumor potency in a mouse model.
    Zhang H; Jia E; Xia W; Lu C; Zhu W
    J Biotechnol; 2018 Oct; 284():84-90. PubMed ID: 30134149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bevacizumab-Induced Inhibition of Angiogenesis Promotes a More Homogeneous Intratumoral Distribution of Paclitaxel, Improving the Antitumor Response.
    Cesca M; Morosi L; Berndt A; Fuso Nerini I; Frapolli R; Richter P; Decio A; Dirsch O; Micotti E; Giordano S; D'Incalci M; Davoli E; Zucchetti M; Giavazzi R
    Mol Cancer Ther; 2016 Jan; 15(1):125-35. PubMed ID: 26494857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. VEGF
    Boudria A; Abou Faycal C; Jia T; Gout S; Keramidas M; Didier C; Lemaître N; Manet S; Coll JL; Toffart AC; Moro-Sibilot D; Albiges-Rizo C; Josserand V; Faurobert E; Brambilla C; Brambilla E; Gazzeri S; Eymin B
    Oncogene; 2019 Feb; 38(7):1050-1066. PubMed ID: 30194450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-tumor effects of ONC201 in combination with VEGF-inhibitors significantly impacts colorectal cancer growth and survival in vivo through complementary non-overlapping mechanisms.
    Wagner J; Kline CL; Zhou L; Khazak V; El-Deiry WS
    J Exp Clin Cancer Res; 2018 Jan; 37(1):11. PubMed ID: 29357916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nab-paclitaxel efficacy in the orthotopic model of human breast cancer is significantly enhanced by concurrent anti-vascular endothelial growth factor A therapy.
    Volk LD; Flister MJ; Bivens CM; Stutzman A; Desai N; Trieu V; Ran S
    Neoplasia; 2008 Jun; 10(6):613-23. PubMed ID: 18516298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bevacizumab promotes active biological behaviors of human umbilical vein endothelial cells by activating TGFβ1 pathways
    Zhang X; Zhang Y; Jia Y; Qin T; Zhang C; Li Y; Huang C; Liu Z; Wang J; Li K
    Cancer Biol Med; 2020 May; 17(2):418-432. PubMed ID: 32587778
    [No Abstract]   [Full Text] [Related]  

  • 12. Anti-Angiogenic Activity Of Bevacizumab-Bearing Dexamethasone-Loaded PLGA Nanoparticles For Potential Intravitreal Applications.
    Liu J; Zhang X; Li G; Xu F; Li S; Teng L; Li Y; Sun F
    Int J Nanomedicine; 2019; 14():8819-8834. PubMed ID: 31819410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of YAP1 as a Marker of Sensitivity to Dual AKT and P70S6K Inhibition in Ovarian and Uterine Malignancies.
    Previs RA; Armaiz-Pena GN; Ivan C; Dalton HJ; Rupaimoole R; Hansen JM; Lyons Y; Huang J; Haemmerle M; Wagner MJ; Gharpure KM; Nagaraja AS; Filant J; McGuire MH; Noh K; Dorniak PL; Linesch SL; Mangala LS; Pradeep S; Wu SY; Sood AK
    J Natl Cancer Inst; 2017 Jul; 109(7):. PubMed ID: 28376174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement of radiation response with bevacizumab.
    Hoang T; Huang S; Armstrong E; Eickhoff JC; Harari PM
    J Exp Clin Cancer Res; 2012 Apr; 31(1):37. PubMed ID: 22538017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-angiogenic effects of trabectedin (Yondelis; ET-743) on human breast cancer cells.
    Atmaca H; Uzunoglu S
    Eur Cytokine Netw; 2014 Mar; 25(1):1-7. PubMed ID: 24941346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bevacizumab combined with apatinib enhances antitumor and anti-angiogenesis effects in a lung cancer model
    Wang M; Zeng Q; Li Y; Imani S; Xie D; Li Y; Han Y; Fan J
    J Drug Target; 2020 Nov; 28(9):961-969. PubMed ID: 32374627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Model driven optimization of antiangiogenics + cytotoxics combination: application to breast cancer mice treated with bevacizumab + paclitaxel doublet leads to reduced tumor growth and fewer metastasis.
    Mollard S; Ciccolini J; Imbs DC; El Cheikh R; Barbolosi D; Benzekry S
    Oncotarget; 2017 Apr; 8(14):23087-23098. PubMed ID: 28416742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eriocalyxin B, a natural diterpenoid, inhibited VEGF-induced angiogenesis and diminished angiogenesis-dependent breast tumor growth by suppressing VEGFR-2 signaling.
    Zhou X; Yue GG; Liu M; Zuo Z; Lee JK; Li M; Tsui SK; Fung KP; Sun H; Pu J; Lau CB
    Oncotarget; 2016 Dec; 7(50):82820-82835. PubMed ID: 27756875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bevacizumab radiosensitizes non-small cell lung cancer xenografts by inhibiting DNA double-strand break repair in endothelial cells.
    Gao H; Xue J; Zhou L; Lan J; He J; Na F; Yang L; Deng L; Lu Y
    Cancer Lett; 2015 Aug; 365(1):79-88. PubMed ID: 25982206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the pro-angiogenic forms of VEGF or inhibiting their expression as anti-cancer strategies.
    Guyot M; Hilmi C; Ambrosetti D; Merlano M; Lo Nigro C; Durivault J; Grépin R; Pagès G
    Oncotarget; 2017 Feb; 8(6):9174-9188. PubMed ID: 27999187
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.